Pfizer Halts Lung Cancer Trials Of Toll-Like Receptor Agent
Fate of other oncology trials of the TLR9 candidate Pfizer licensed from Coley has not been made public.
Fate of other oncology trials of the TLR9 candidate Pfizer licensed from Coley has not been made public.